Adaptimmune Therapeutics's total assets for Q4 2024 were $245.96M, a decrease of -22.52% from the previous quarter. ADAP total liabilities were $234.11M for the fiscal quarter, a -1.40% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.